SOFTMEDX-NEW (00648) announced its interim results for 2025, reporting revenue of HK$35.771 million, representing a 16.5% increase year-on-year. Profit attributable to shareholders reached HK$3.353 million, compared to a loss attributable to shareholders of HK$6.093 million in the same period last year, successfully turning from loss to profit. Basic earnings per share stood at 1 HK cent. According to the announcement, the revenue growth was primarily attributed to the group's continuous efforts to expand product sources and broaden its product portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.